{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.","groups":[{"description":"Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)"},{"description":"Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (Topotecan Hydrochloride, Carboplatin)"}],"populationDescription":"Data was not collected.","reportingStatus":"POSTED","timeFrame":"Up to 7 months","title":"Number of Participants With Minimal Residual Disease (MRD) After Treatment","type":"SECONDARY"}